KEYMED BIOSCIENCES -0001
Research KEYMED BIOSCIENCES -0001 (64Z) on Bullrun: market cap EUR 1.89B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker64Z
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.89B
- Financial periodFY2025
- RevenueEUR 716.31M
- Revenue growth67.3%
- Net income-EUR 522.64M
- Free cash flow-EUR 1.05B
- Gross margin87.7%
Valuation Snapshot
latest market cap is EUR 1.89B.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors;
Frequently asked questions
What is KEYMED BIOSCIENCES -0001's market cap?
KEYMED BIOSCIENCES -0001's market capitalization is EUR 1.89B.
What does KEYMED BIOSCIENCES -0001 do?
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom.